蜜桃传媒app

听

According to the paper published in the Journal of the International AIDS Society, social welfare recipients and others who do not have paid employment struggle for early access to necessary ART despite access to universal health care. Early ART is a key factor in reducing AIDS and non-AIDS events, including cardiovascular, renal, hepatic and neurocognitive disorders, and cancer among persons living with HIV. In addition, early treatment also significantly decreases the risk of HIV transmission.

听

鈥淭his paper shows we need to take socio-economic factors into consideration when it comes to better controlling the HIV epidemic in Canada. People who are vulnerable economically may be put at greater risk because access to ART is delayed,鈥� says study lead author Dr. Jean-Pierre Routy, a senior scientist from the Infectious Diseases and Immunity in Global Health (IDIGH) Program at the RI-MUHC and a hematologist at the Chronic Viral Illness Service of the MUHC.

听

From 1996 to 2015, Dr. Routy鈥檚 Montreal-based research team looked at a cohort of 549 participants, early in their HIV infection determining those who count on income security such as social assistance and employment insurance benefits were not accessing ART early. Indeed, working persons earning a salary were two-and-a-half times more likely to initiate early ART compared to this group.

听

This delayed access represents a potential setback in fighting HIV in Quebec. Despite the availability of universal health care and medication insurance, care appears to be inequitable.听听

听

鈥淧eople who are unemployed and depend on income support are faced with tough daily decisions on how they use limited resources. Competing needs may lead to less capacity to engage in care and related expenses. This population needs aid,鈥� explains Dr. Routy, who is also a professor in the Department of Medicine, Division of Hematology at the Faculty of Medicine of McGill University.

听

鈥淭his study is very important because it demonstrates that people delay or end their treatment due to financial reasons, putting their own health at risk,鈥� says study co-author, Dr. R茅jean Thomas, founder and president of L'Actuel Medical Clinic in Montreal. 鈥淲e鈥檙e talking about a very worrying public health matter since we鈥檝e known for years that an HIV-infected person with an undetectable viral load undergoing antiretroviral treatment cannot transmit the disease.鈥澨�

听

鈥淚n a specialized clinic like l鈥橝ctuel, over 90 per cent of diagnosed patients begin treatment very early after their diagnosis compared to 30 per cent just 10 years ago,鈥� adds Dr. Thomas.

听

鈥淭he effect of type of care centres on early treatment initiation was an interesting finding that we did not expect,鈥� adds first study author Dr. Vikram Mehraj, postdoctoral fellow in the IDIGH Program at the RI-MUHC. 鈥淲e believe this finding can be explained in part by the fact that sicker patients may preferentially use university-medical centres.鈥�

听

Unlike in British Columbia or France, ART for persons living with HIV in Quebec is still not entirely free. Dr. Thomas points to the obstacle of annual charges for treatment ranging from $28,000 to $36,000.

听

鈥淚f we want to eradicate HIV by 2030 鈥� in line with the UNAIDS objectives signed by the city of Montreal on December 1, 2017 鈥� we will have to seriously examine this obstacle moving forward,鈥� says Dr. Thomas.

听

The study Socio鈥恊conomic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996 to 2015 was co-authored by Vikram Mehraj, Joseph Cox, Bertrand Lebouche, Cecilia Costiniuk, Wei Cao, Taisheng, Rosalie Ponte, Rejean Thomas, Jason Szabo, Jean-Guy Baril, Benoit Trottier, Pierre C么t茅, Roger LeBlanc, Julie Bruneau, Cecile Tremblay, Jean-Pierre Routy and the Montreal Primary HIV-Infection Study Group (see paper for the entire list of authors).听

听

This work was supported by the Fonds de la Recherche Quebec-Sante (FRQ-S): Reseau SIDA/Maladies infectieuses and Therapie cellulaire; the Canadian Institutes of Health Research (CIHR; grants MOP 103230 and 154051); the Vaccines & Immunotherapies Core of the CIHR Canadian HIV Trials Network (CTN; grant CTN 257); the Canadian Foundation for AIDS Research (CANFAR; grant 02-512); and the Canadian HIV Cure Enterprise Team Grant (HIG-133050) awarded by the CIHR in partnership with CANFAR.

听

Mehraj V. et coll., Journal of the International AIDS Society 2018, 21:e25034

| 听

听

听The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) 鈥� an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 420 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC. Its research facilities offer a dynamic multidisciplinary environment that fosters collaboration and leverages discovery aimed at improving the health of individual patients across their lifespan. The RI-MUHC is supported in part by the Fonds de recherche du Qu茅bec 鈥� Sant茅 (FRQS).

听

Communications Coordinator/Media Relations

McGill University Health Centre听

514-210-6376 (cell)

514-934-1934, xt 34319听